Synairgen (LON:SNG) Sets New 1-Year Low – Here’s Why

Posted by Anthony Miller on Mar 19th, 2025

Synairgen plc (LON:SNG – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 0.72 ($0.01) and last traded at GBX 0.93 ($0.01), with a volume of 1287395 shares changing hands. The stock had previously closed at GBX 0.96 ($0.01).

Synairgen Trading Down 3.0 %

The stock has a market capitalization of £9.10 million, a P/E ratio of -0.56 and a beta of -2.23. The company has a 50-day moving average price of GBX 1.91 and a 200 day moving average price of GBX 3.25.

About Synairgen

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).